MORE►
oncology
Senderra CEO and founder Will Howard [Composite image: DI Studio; Sources: Senderra, ilyaliren/istockphoto]
Dallas-Based SenderraRx Gets Growth Investment from Rhode Island’s Nautic Partners
by Sandra Engelland | Dec 13, 2025
Founded in 2010, SenderraRx said it has made a name for itself in the specialty pharmacy space by focusing on therapies for patients with complex and chronic conditions in areas such as dermatology, rheumatology, and oncology.
by Quincy Preston |
Oct 14, 2025
The North Texas biotech, which uses AI to accelerate cancer drug development, received FDA feedback to advance a new clinical study targeting a rare childhood brain tumor.
MORE►
by Lance Murray |
Jul 15, 2025
Argon—a provider of medical device solutions for Interventional radiology, vascular surgery, interventional cardiology, and oncology procedures—said its new Distribution & Education Center in Derby, England, will serve as a a hub for more than 80 countries across Europe, Africa, the Middle East, and the Asia-Pacific region.
MORE►
Instil Bio Chief Medical Officer Jamie Freedman, MD, PhD [Photo: LinkedIn]
Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer
by Lance Murray | Jun 5, 2025
Dallas' Instil Bio said that Jamie Freedman has extensive experience in oncology drug development and other therapeutic areas, along with a track record of leading programs through all phases of development, regulatory approval, and commercialization.
MORE►
by Lance Murray |
Apr 22, 2025
Precision Care Companion (PCC) is a consortium of industry experts, led by McKesson, designed to help healthcare practices improve patient care.
MORE►
by Lance Murray |
Aug 26, 2024
Florida-based Core Ventures was established by the Florida Cancer Specialists & Research Institute, a physician-owned community oncology practice. With the multi-billion-dollar acquisition, CORE Ventures will join McKesson's US Oncology Network to advance "affordable cancer care and better patient outcomes."
MORE►
by Lance Murray |
Jun 1, 2023
Expanding a collaboration they announced in January, the two companies aim to drive "the future of cancer care" with the new platform, enabling novel insights for precision medicine, therapeutic development, and clinical trials management for academic and biopharma researchers.
MORE►
Lantern Pharma CEO Panna Sharma [Courtesy: Lantern Pharma]
Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise
by Quincy Preston | Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
MORE►
by Kevin Cummings |
Jun 2, 2022
Instead of shipping a patient's blood to a lab for customized cell therapy, Lupagen does the procedure "in vivo," using a dialysis-like treatment at the patient's bedside. Now it's collaborating with Umoja Biopharma to use its drug-delivery tech to place targeted immunotherapies in patients.
“We're able to deliver different types of gene therapies in a closed system," Lupagen's CEO says, calling the tech a "bridge to the future."
“We're able to deliver different types of gene therapies in a closed system," Lupagen's CEO says, calling the tech a "bridge to the future."
MORE►
by Alex Edwards |
Dec 9, 2020
Ontada builds on McKesson's long history in community oncology. The new business will combine McKesson's real-world data and research capabilities, technology, and ties to the national community oncology network to transform cancer care.
MORE►
by Alex Edwards |
Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
[Photo by Sudok1 via iStock]
Fort Worth Cancer Center Wins Innovator Award
by Julia Batlle | Feb 14, 2017
The Foley and Lardner LLP award recognizes effective business models and strategies for cancer care providers.
MORE►
by Patrick Kobler |
Feb 9, 2016
We connected with Dr. Theodora Ross, author of A Cancer in the Family, on why she came to DFW, UT Southwestern’s work in cancer genetics, and for her thoughts on how we can battle cancer more effectively.
MORE►
